Innate Pharma S.A. (EPA: IPH)
France
· Delayed Price · Currency is EUR 1.532
+0.004 (0.26%)
Nov 22, 2024, 5:35 PM CET
Innate Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 24.85 | 51.9 | 49.58 | 12.11 | 56.16 | 68.61 | Upgrade
|
| Other Revenue | 8.94 | 9.74 | 8.09 | 12.59 | 13.62 | 16.84 | Upgrade
|
| Revenue | 33.79 | 61.64 | 57.67 | 24.7 | 69.77 | 85.45 | Upgrade
|
| Revenue Growth (YoY) | -35.37% | 6.88% | 133.47% | -64.60% | -18.35% | -9.05% | Upgrade
|
| Cost of Revenue | 53.65 | 56.02 | 51.66 | 47 | 49.71 | 62.9 | Upgrade
|
| Gross Profit | -19.86 | 5.62 | 6.01 | -22.3 | 20.07 | 22.55 | Upgrade
|
| Selling, General & Admin | 18.73 | 18.29 | 22.44 | 25.52 | 18.99 | 20.98 | Upgrade
|
| Operating Expenses | 18.73 | 18.29 | 22.44 | 25.52 | 18.99 | 20.98 | Upgrade
|
| Operating Income | -38.58 | -12.67 | -16.43 | -47.83 | 1.08 | 1.58 | Upgrade
|
| Interest Expense | -0.62 | -0.64 | -0.29 | -0.31 | -0.34 | -0.2 | Upgrade
|
| Interest & Investment Income | 3.48 | 3.18 | 0.55 | 0.33 | 0.56 | 1.62 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.41 | 0.91 | 0.83 | 1.25 | -1.58 | 0.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.07 | 1.65 | -1.63 | 1.08 | -0.55 | 4.08 | Upgrade
|
| EBT Excluding Unusual Items | -34.05 | -7.57 | -16.97 | -45.48 | -0.83 | 7.87 | Upgrade
|
| Asset Writedown | - | - | -41 | - | - | - | Upgrade
|
| Pretax Income | -34.05 | -7.57 | -57.97 | -45.48 | -0.83 | 7.87 | Upgrade
|
| Earnings From Continuing Operations | -34.05 | -7.57 | -57.97 | -45.48 | -0.83 | 7.87 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -0.13 | -7.33 | -63.16 | -28.63 | Upgrade
|
| Net Income | -34.05 | -7.57 | -58.1 | -52.81 | -63.98 | -20.76 | Upgrade
|
| Net Income to Common | -34.05 | -7.57 | -58.1 | -52.81 | -63.98 | -20.76 | Upgrade
|
| Shares Outstanding (Basic) | 81 | 80 | 80 | 80 | 79 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 81 | 80 | 80 | 80 | 79 | 67 | Upgrade
|
| Shares Change (YoY) | 1.01% | 1.02% | 0.12% | 0.77% | 17.97% | 13.83% | Upgrade
|
| EPS (Basic) | -0.42 | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | Upgrade
|
| EPS (Diluted) | -0.42 | -0.09 | -0.73 | -0.66 | -0.81 | -0.31 | Upgrade
|
| Free Cash Flow | -18.38 | -32.91 | -19.69 | -59.39 | -52.67 | 33.65 | Upgrade
|
| Free Cash Flow Per Share | -0.23 | -0.41 | -0.25 | -0.75 | -0.67 | 0.50 | Upgrade
|
| Gross Margin | -58.77% | 9.12% | 10.42% | -90.28% | 28.76% | 26.39% | Upgrade
|
| Operating Margin | -114.19% | -20.55% | -28.48% | -193.60% | 1.55% | 1.84% | Upgrade
|
| Profit Margin | -100.78% | -12.28% | -100.74% | -213.78% | -91.70% | -24.29% | Upgrade
|
| Free Cash Flow Margin | -54.40% | -53.39% | -34.14% | -240.40% | -75.49% | 39.38% | Upgrade
|
| EBITDA | -35.96 | -7.58 | -12.02 | -43.23 | 13.31 | 17.25 | Upgrade
|
| EBITDA Margin | -106.43% | -12.29% | -20.84% | -174.99% | 19.07% | 20.19% | Upgrade
|
| D&A For EBITDA | 2.62 | 5.09 | 4.41 | 4.6 | 12.23 | 15.68 | Upgrade
|
| EBIT | -38.58 | -12.67 | -16.43 | -47.83 | 1.08 | 1.58 | Upgrade
|
| EBIT Margin | -114.19% | -20.55% | -28.48% | -193.60% | 1.55% | 1.84% | Upgrade
|
| Revenue as Reported | 33.79 | 61.64 | 57.67 | 24.7 | 69.77 | 85.45 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.